From CGMPs to the Critical Path: FDA Focuses on Innovation, Quality, and Continuous Improvement–Inside and Out
By Laura Bush
News
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2004
Volume 28
Issue 7
As FDA prepares for the Critical Path initiative, offices across the agency are expanding the use of the risk-based approach to regulation and applying a quality systems approach to internal operations.
Articles in this issue
3M Drug Delivery Systems
AccuRate
July 2004
Characterization of the Performance of Bin Blenders Part 2 of 3: Free-Flowing Mixtures
Investors Shy Away from Pharmaceutical Chemicals
From CGMPs to the Critical Path: FDA Focuses on Innovation, Quality, and Continuous Improvement–Inside and Out
In the Spotlight-July 2004
The LR Method in Critical Areas: Airflow Patterns and the Design of Aseptic Interventions
A Stability Program for the Distribution of Drug Products
Politics Versus Science in Biomedical Research and Development
Recent Videos
Related Content
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Article
Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
